1.
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
by Barlesi, Fabrice
The lancet oncology, 2018, Vol.19 (11), p.1468-1479
2.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
by Balar, Arjun V, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.67-76
3.
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
by Cameron, David, Prof
The Lancet (British edition), 2017, Vol.389 (10075), p.1195-1205
4.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
by Herbst, Roy S, Prof
The Lancet (British edition), 2015, Vol.387 (10027), p.1540-1550
5.
Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation
by Miao, Lei
Nature biotechnology, 2019, Vol.37 (10), p.1174-1185
6.
S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
by Koizumi, Wasaburo, Dr
The lancet oncology, 2008, Vol.9 (3), p.215-221
7.
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomi...
by Seymour, Matthew T, Prof
The lancet oncology, 2013, Vol.14 (8), p.749-759
8.
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
by Schöffski, Patrick, Prof
The Lancet (British edition), 2016, Vol.387 (10028), p.1629-1637
9.
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial
by Bruix, Jordi, Prof
The lancet oncology, 2015, Vol.16 (13), p.1344-1354
10.
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
by Bruix, Jordi, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.56-66
11.
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysi...
by McQuade, Jennifer L
The lancet oncology, 2018, Vol.19 (3), p.310-322
12.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
by Ribas, Antoni, Prof
The lancet oncology, 2015, Vol.16 (8), p.908-918
13.
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
by Souers, Andrew J
Nature medicine, 2013, Vol.19 (2), p.202-208
14.
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
by Heery, Christopher R, MD
The lancet oncology, 2017, Vol.18 (5), p.587-598
15.
Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy
by Rady, Islam
Cancer letters, 2017, Vol.402, p.16-31
16.
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
by Lonial, Sagar, Prof
The Lancet (British edition), 2016, Vol.387 (10027), p.1551-1560
17.
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour act...
by Wilson, Wyndham H, Prof
The lancet oncology, 2010, Vol.11 (12), p.1149-1159
18.
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
by Fesik, Stephen W
Nature, 2005, Vol.435 (7042), p.677-681
19.
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label pha...
by Hillmen, Peter, Prof
The Lancet (British edition), 2015, Vol.385 (9980), p.1873-1883
20.
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
by Mossé, Yael P, Dr
The lancet oncology, 2013, Vol.14 (6), p.472-480
